{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:52:05Z","timestamp":1782417125568,"version":"3.54.5"},"reference-count":67,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2021,1,2]]},"DOI":"10.1080\/14712598.2020.1811849","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:57:36Z","timestamp":1597798656000},"page":"37-46","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":24,"title":["Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13"],"prefix":"10.1080","volume":"21","author":[{"given":"Tommaso Lorenzo","family":"Parigi","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Humanitas Clinical and Research Center - IRCCS, IBD Center, Milan, Italy"},{"name":"Department of Biomedical Sciences, Pieve Emanuele, Humanitas University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"cit0001","doi-asserted-by":"crossref","unstructured":"Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis.\u00a0Lancet. 2017;389(10080):1756\u20131770. DOI:10.1016\/S0140-6736(16)32126-2.","DOI":"10.1016\/S0140-6736(16)32126-2"},{"key":"cit0002","doi-asserted-by":"crossref","unstructured":"Torres J, Mehandru S, Colombel JF, et al. Crohn's disease.\u00a0Lancet. 2017;389(10080):1741-1755. DOI:10.1016\/S0140-6736(16)31711-1.","DOI":"10.1016\/S0140-6736(16)31711-1"},{"key":"cit0003","first-page":"4","volume":"2020","author":"Torres J","year":"2019","journal-title":"J Crohn\u2019s Colitis"},{"key":"cit0004","doi-asserted-by":"crossref","unstructured":"Danese S, Fiorino G, Peyrin-Biroulet L. Positioning therapies in ulcerative colitis. W.B. Saunders; 2020. p. 1280\u20131290.e1. Clin. Gastroenterol. Hepatol. * This study reports the most recent evidence for the therapeutic management of patients with ulcerative colitis.","DOI":"10.1016\/j.cgh.2020.01.017"},{"key":"cit0005","unstructured":"Table 1, cost comparison table of biologics for the treatment of Crohn\u2019s Disease - Entyvio (Vedolizumab) - NCBI Bookshelf [Internet]. [cited 2020 May 30]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK424364\/table\/T68\/."},{"key":"cit0006","unstructured":"3 The technologies | infliximab and adalimumab for the treatment of Crohn\u2019s disease | guidance | NICE [Internet]. [cited 2020 May 30]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta187\/chapter\/3-the-technologies."},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01256-5"},{"key":"cit0008","first-page":"1685","volume":"2016","author":"Ben-Horin S","journal-title":"Clin Gastroenterol Hepatol"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.07.021"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.008"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21818"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S207246"},{"key":"cit0013","unstructured":"Remsima | European Medicines Agency [Internet]. [cited 2020 May 24]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remsima."},{"key":"cit0014","unstructured":"Inflectra. European Medicines Agency [Internet]. [cited 2020 May 24]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/inflectra."},{"key":"cit0015","unstructured":"US Food and Drug Administration. Inflectra Prescribing Information. [Internet]. [cited 2020 May 24]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125544s009lbl.pdf."},{"key":"cit0016","unstructured":"Medicines Agency E. Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues [Internet]. 2014 [cited 2020 May 24]. Available from: www.ema.europa.eu\/contact."},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203090"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203091"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12880"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001237"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz070"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13990"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-019-03354-7"},{"key":"cit0025","volume":"25","author":"LJT S","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"cit0026","first-page":"12","author":"Guerra Veloz MF","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2018.1463391"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002011"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000601"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0110-9"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2019.11.004"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1512406"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14509"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.10.002"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14453"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2418-4"},{"issue":"1320","key":"cit0037","volume":"148","author":"Vande Casteele N","year":"2015","journal-title":"Gastroenterology"},{"issue":"1276","key":"cit0038","volume":"16","author":"Pouillon L","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30082-7"},{"key":"cit0040","doi-asserted-by":"crossref","unstructured":"Bonovas S, Peyrin-Biroulet L, Danese S. Infliximab biosimilar CT-P13 for inflammatory bowel disease.\u00a0Lancet Gastroenterol Hepatol. 2018;3(6):373\u2013375. DOI:10.1016\/S2468-1253(18)30116-X.","DOI":"10.1016\/S2468-1253(18)30116-X"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283521c4e"},{"key":"cit0042","unstructured":"Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). [Internet]. 2009. [cited 2020 May 24]. Available from: https:\/\/www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf."},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00394-x"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-016-0174-5"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx009"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0219-4"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208684"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14808"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309290"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1002\/art.40324"},{"key":"cit0051","author":"Westhovens R","journal-title":"Ann Rheum Dis"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(18)34477-9"},{"key":"cit0053","author":"Yoo D","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"cit0054","doi-asserted-by":"crossref","unstructured":"DOP62 A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn\u2019s disease. J Crohn\u2019s Colitis. [Oxford Academic [Internet]. [cited 2020 May 1]. Available from: https:\/\/academic.oup.com\/ecco-jcc\/article\/13\/Supplement_1\/S066\/5301215","DOI":"10.1093\/ecco-jcc\/jjy222.096"},{"key":"cit0055","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/2050640619888859","volume":"7","author":"Schreiber S","year":"2019","journal-title":"United Eur Gastroenterol J"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(20)31165-3"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.233"},{"key":"cit0058","first-page":"1754","author":"Ord\u00e1s I","journal-title":"Gut"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2016.1126247"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0233-1"},{"key":"cit0061","first-page":"15(Suppl 1):S65","author":"Brodszky V","year":"2014","journal-title":"Eur J Heal Econ"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1002\/art.41201"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1002\/art.41203"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-06036-0"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S170913"},{"key":"cit0066","unstructured":"Zhu LR MR and FG on behalf of the C-19 ET. 2nd Interview COVID-19 ECCO Taskforce [Internet]. 2020 [cited 2020 Jun 1]. Available from: https:\/\/www.ecdc.europa.eu\/en\/current-risk-assessment-novel-coronavirus-"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2017.1264717"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2020.1811849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T17:09:40Z","timestamp":1659805780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2020.1811849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,2]]}},"alternative-id":["10.1080\/14712598.2020.1811849"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2020.1811849","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}